Evidence map›Paper›PMID 39164484›Full record

ArticleBone marrow transplantation2024

Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT.

Arnon Nagler, Myriam Labopin, Urpu Salmenniemi, Depei Wu, Didier Blaise, Alessandro Rambaldi, Péter Reményi, Edouard Forcade, Gérard Socié, Patrice Chevallier and 11 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Arnon NaglerDivision of Hematology, Sheba Medical Center, Tel Hashomer, Israel. arnon.nagler@sheba.health.gov.il.ORCID http://orcid.org/0000-0002-0763-1265
Myriam LabopinEBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.ORCID http://orcid.org/0000-0003-4514-4748
Urpu SalmenniemiHUCH Comprehensive Cancer Center, Helsinki, Finland.
Depei WuFirst Affiliated Hospital of Soochow University, Suzhou, China.
Didier BlaiseProgramme de Transplantation & Therapie Cellulaire, Marseille, France.
Alessandro RambaldiDepartment of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Péter ReményiDél-pesti Centrumkórház, Budapest, Hungary.
Edouard ForcadeCHU Bordeaux, Hopital Haut-L'évêque, Pessac, France.
Gérard SociéUniversity Paris Cité, INSERM UMR 976, APHP- Saint-Louis Hospital, BMT Unit, Paris, France.ORCID http://orcid.org/0000-0002-2114-7533
Patrice ChevallierCHU Nantes, Nantes, France.ORCID http://orcid.org/0000-0003-3142-5581
Peter von dem BorneLeiden University Medical Center, Leiden, The Netherlands.ORCID http://orcid.org/0000-0002-7470-7346
David BurnsUniversity Hospital Birmingham NHS Trust, Stoke, UK.
Christoph SchmidKlinikum Augsburg, Augsburg, Germany.ORCID http://orcid.org/0000-0001-7070-487X
Johan MaertensUniversity Hospital Gasthuisberg, Leuven, Belgium.ORCID http://orcid.org/0000-0003-4257-5980
Nicolaus KrögerUniversity Medical Center Hamburg, Hamburg, Germany.
Gesine BugGoethe-Universitaet, Frankfurt Main, Germany.ORCID http://orcid.org/0000-0003-2359-131X
Mahmoud AljurfKing Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.ORCID http://orcid.org/0000-0003-3942-7370
Jan VydraInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-4274-3895
Kazimierz HalaburdaInstitute of Hematology and Transfusion Medicine, Warsaw, Poland.
Fabio CiceriIRCCS Osspedale San Raffaele, Vita-Salute San Raffaele University Haematology and BMT, Milano, Italy.ORCID http://orcid.org/0000-0003-0873-0123
Mohamad MohtyEBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.ORCID http://orcid.org/0000-0002-7264-808X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We assessed outcomes of allogeneic transplantation (HSCT) in favorable risk AML in CR1 over 3 time periods. 1850 patients were included, 2005 to 2009- 222, 2010 to 2014 -392, and 2015 to 2021-1236; 526 with t (8:21), 625 with inv (16), and 699 with NPM1

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdolescentAdultAgedAllograftsFemaleGraft vs Host DiseaseHumansLongitudinal StudiesMaleMiddle AgedNucleophosminRemission InductionRetrospective StudiesTransplantation, HomologousNucleophosmin

Identifiers

PMID39164484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.